



Sep 14, 2016

Senju Pharmaceutical Co., Ltd.  
Otsuka Pharmaceutical Co., Ltd

## **Announcement of co-promotion of new glaucoma treatment**

Senju Pharmaceutical., Co. Ltd. and Otsuka Pharmaceutical Co., Ltd announce the signing of a new agreement to co-promote in Japan an additional new treatment for glaucoma and ocular hypertension.

.

The two companies have an existing agreement to market Mikelan ophthalmic solution and Mikelan Long-Acting ophthalmic solution, treatments developed by Otsuka for glaucoma and ocular hypertension. The new contract reflects the decision to co-promote in Japan the combined ophthalmic solution carteolol hydrochloride/latanoprost (OPC-1085EL), which has been submitted by Otsuka for new drug approval in Japan.

In addition, the new contract includes provisions to co-promote future ophthalmic preparation that Senju has scheduled to enter clinical development. Furthermore, at the signing of the contract no additional milestone or lump sum payment are made.